1. A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Issue 6 (23rd December 2021) Authors: Yurdaydin, Cihan; Keskin, Onur; Yurdcu, Esra; Çalişkan, Aysun; Önem, Soner; Karakaya, Fatih; Kalkan, Çağdaş; Karatayli, Ersin; Karatayli, Senem; Choong, Ingrid; Apelian, David; Koh, Christopher; Heller, Theo; Idilman, Ramazan; Bozdayi, A. Mithat; Glenn, Jeffrey S. Journal: Hepatology Issue: Volume 75:Issue 6(2022) Page Start: 1551 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SaO018FACTOR D INHIBITION WITH ACH-4471 TO REDUCE COMPLEMENT ALTERNATIVE PATHWAY HYPERACTIVITY AND PROTEINURIA IN C3 GLOMERULOPATHY: PRELIMINARY PROOF OF CONCEPT DATA. (18th May 2018) Authors: Kocinsky, Hetal; Kelleher, Cass; Apelian, David; Bulawski, Angela; Geffner, Michael; Huang, Mingjun; Price, John; Yang, Joanna; Yang, Wengang; Zhao, Yongsen; van de Kar, Nicole; Wetzels, Jack; Bouman, Koen; Cook, Terence; Barbour, Tom Journal: Nephrology dialysis transplantation Issue: Volume 33(2018)Supplement 1 Page Start: i322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial. Issue 3 (April 2018) Authors: Cohn, Allen; Morse, Michael A.; O'Neil, Bert; Whiting, Samuel; Coeshott, Claire; Ferraro, John; Bellgrau, Donald; Apelian, David; Rodell, Timothy C. Journal: Journal of immunotherapy Issue: Volume 41:Issue 3(2018:Apr.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗